Clinical Evidence

Clinical benefits for a broad range of T1D and T2D patients

A health care professional sitting and smiling
A health care professional sitting and smiling
A health care professional sitting and smiling

Decreases HbA1c3-6

Increases Time in Range1

Reduces Hypoglycaemia1,2

Clinical Outcomes for T1D

Significant HbA1c reduction

FLASH UK RCT Study1

FreeStyle Libre 2 users reduced their HbA1c by 0.5% compared to SMBG at 6 months of use.1,*

Increased Time in Range graph

2.2 hours more Time in Range per day

FLASH UK RCT Study1

An independent study published in the New England Journal of Medicine shows that FreeStyle Libre 2 users spent 2.2 hours more time in range per day at 6 months of use vs those using self-monitored blood glucose (SMBG).1,*

Increased Time in Range graph

Significant reduction in time spend in hypoglycaemia

FLASH UK RCT Study1

The FreeStyle Libre 2 system is proven to reduce time spent in hypoglycaemia (<3.9 mmol/L) significantly, with 43 minutes less time in hypoglycaemia per day vs SMBG.1,*

 

Increased Time in Range graph § Adjusted Mean Difference (95% CI)

Significant HbA1c reduction in patients using insulin and non-insulin therapies3-5

On rapid or short-acting insulin3

p<0.0001

On basal insulin4

p<0.0001

On non-insulin therapies5

p<0.001

Clinical Outcomes for T2D

Significantly reduces time spent in hypoglycaemia

for T2D on MDI

REPLACE Study2

A 6-month RCT in 224 T2D patients on intensive insulin therapy proves the FreeStyle Libre systems safely and successfully replaces SMBG.2,*

Increased Time in Range graph

Reduces nocturnal hypoglycaemia

REPLACE Study2

(<3.9 mmol/L, time in hour, from 11:00 pm to 6:00 am)
(p<0.0001)

Reduces severe hypoglycaemia

REPLACE Study2

(<3.1 mmol/L, time in hour, within 24 hours)
(p<0.0014)

Making Better Choices

The FreeStyle Libre portfolio helps patients with T1D and T2D make better choices

Better understanding of glucose fluctuations:

Real World data showed that 95% of patients with T1D and T2D using the FreeStyle Libre system have a better understanding of their glucose fluctuations.7

Lifestyle modifications can help lower HbA1c

Patients with T2D who make lifestyle changes, such as diet and physical activity, see improved glucose control.8

A woman and a man with mugs in their hands sitting at the table full of food.

Improved Glycaemic Control in ChildrenѰ

Children and teenagers can successfully improve their glycaemic control with the FreeStyle Libre portfolio

1 hr/day

increase in time in range 

(3.9–10.0 mmol/L)

0.4%

reduction in HbA1c9

1.2 hr/day

less time spent in hyperglycaemia9

(>10 mmol/L) with no significant increase in time spent in hypoglycaemia (<3.9 mmol/L)

90%

of children and teenagers agreed that the FreeStyle Libre system did not get in the way of daily activities9

Additional Resources

Real-World Data

Analysing the impact of the FreeStyle Libre systems on the lives of real users.
 

Educational Modules

Learn more about Time in Range and the FreeStyle Libre portfolio through our Healthcare Professional education modules.

Webinars

We offer various on-demand webinars for Healthcare Professionals including a spotlight on hypoglycaemia.

    

Webcast Series

Learn more about Time in Range in our CME accredited three-module webcast series.

    

Training Resources

Explore our training resources to help you to help your patients understand Time in Range better.

References & Disclaimers

Images are for illustrative purposes only. Not real patient or data.

* FreeStyle Libre systems refers to the FreeStyle Libre and FreeStyle Libre 2 systems. The data from this study was collected using the FreeStyle Libre 2 system. FreeStyle Libre system has the same features as the FreeStyle Libre 2 system with the exception of alarms therefore the study data is applicable to both products.

Ѱ For children aged 4-12, a caregiver at least 18 years old is responsible for supervising, managing, and assisting them in using the FreeStyle Libre system and interpreting its readings.

1. Leelarathna, L. N Engl J Med. (2022): DOI: 10.1056/NEJMoa2205650.

2. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6.

3. Kroger J., Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9.

4. Carlson AL. BMJ Open Diab Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590.

5. Wright, E. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069.

6. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166.

7. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.

8. American Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45 (Suppl. 1):S60–S82.

9. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294–301. 

Loading...